{"gene":"SYT11","run_date":"2026-06-10T10:51:54","timeline":{"discoveries":[{"year":2016,"finding":"ATP13A2 depletion negatively regulates SYT11 at both transcriptional and post-translational levels: decreased SYT11 transcription is controlled by MYCBP2-induced ubiquitination of TSC2, leading to mTORC1 activation and decreased TFEB-mediated transcription of SYT11, while increased protein turnover is regulated by SYT11 ubiquitination and degradation. Decreased SYT11 levels in turn induce lysosomal dysfunction and impaired degradation of autophagosomes.","method":"Genetic knockdown, epistasis analysis, transcriptional reporter assays, ubiquitination assays, lysosomal function assays","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (knockdown, epistasis, ubiquitination, lysosomal function assays) in a single study, replicated across conditions","pmids":["27278822"],"is_preprint":false},{"year":2018,"finding":"Synaptotagmin-11 is a physiological substrate of parkin (E3 ubiquitin ligase). Parkin deficiency leads to synaptotagmin-11 accumulation. Unilateral overexpression of full-length (but not C2B-truncated) synaptotagmin-11 in the substantia nigra pars compacta impairs striatal dopamine release by inhibiting endocytosis and vesicle pool replenishment, causing late-onset dopaminergic neuron degeneration and progressive motor abnormalities. SYT11 knockdown or knockout in dopaminergic neurons reversed parkin-deficiency-induced PD-like neurotoxicity.","method":"In vivo overexpression (viral vector), knockout mice, dopamine release measurements, electron microscopy, genetic rescue experiments","journal":"Nature communications","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal in vivo methods (overexpression, knockout, rescue), mechanistic dissection with truncation mutant, replicated across models","pmids":["29311685"],"is_preprint":false},{"year":2019,"finding":"In neurons, Syt11 resides on abundant vesicles resembling trafficking endosomes (distinct from synaptic vesicles) that recycle via the plasma membrane in an activity-dependent manner with slow, desynchronized exocytosis. Constitutive Syt11 knockout mice die shortly after birth. Conditional knockout of Syt11 in excitatory forebrain neurons impairs long-term synaptic potentiation and memory without affecting fast neurotransmitter or peptide secretion.","method":"Conditional and constitutive knockout mice, live-cell imaging, electrophysiology, memory behavioral assays, vesicle fractionation","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 / Strong — constitutive and conditional knockout models with multiple orthogonal phenotypic readouts, live imaging for localization","pmids":["30808661"],"is_preprint":false},{"year":2017,"finding":"Syt11 inhibits cytokine secretion and phagocytosis in microglia. Syt11 knockdown increases IL-6, TNF-α, IL-1β, and iNOS synthesis and activates NF-κB. Syt11 specifically regulates conventional secretion of IL-6 and TNF-α. Syt11 localizes to the trans-Golgi network and recycling endosomes and is recruited to phagosomes. Syt11 deficiency enhances phagocytosis including that of α-synuclein fibrils. All KD phenotypes were rescued by shRNA-resistant Syt11.","method":"shRNA knockdown in primary microglia, overexpression rescue, ELISA, NF-κB reporter, immunofluorescence/confocal microscopy, phagocytosis assay","journal":"Glia","confidence":"High","confidence_rationale":"Tier 2 / Strong — knockdown with rescue controls, multiple orthogonal functional readouts (secretion, phagocytosis, signaling), localization experiments","pmids":["28686317"],"is_preprint":false},{"year":2021,"finding":"Syt11 suppresses spontaneous (miniature) excitatory neurotransmission. Syt11-KO hippocampal neurons show increased mEPSC frequency; Syt11 overexpression decreases mEPSC frequency without affecting amplitude, indicating presynaptic regulation. Syt11 directly interacts with the non-canonical SNARE protein vti1a (C2A domain of Syt11 binds vti1a with high affinity), and vti1a knockdown reverses the Syt11-KO phenotype, identifying vti1a as the primary target.","method":"Knockout and overexpression in hippocampal neurons, electrophysiology (mEPSC recording), GST pull-down, co-immunoprecipitation, affinity purification, domain deletion analysis","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct binding established by GST pull-down and Co-IP, epistasis by vti1a KD rescue, electrophysiology, domain mapping","pmids":["34599505"],"is_preprint":false},{"year":2023,"finding":"Syt11 is palmitoylated at Cys39 and Cys40 (adjacent to its transmembrane domain) in mouse and human brain tissue and cultured neurons. Palmitoylation localizes Syt11 to digitonin-insoluble intracellular membranes and protects it from endolysosomal degradation. Palmitoylated Syt11 increases its own abundance and enhances α-synuclein binding to intracellular membranes, decreasing the physiologic tetrameric form and increasing the aggregation-prone monomeric form. A palmitoylation-deficient mutant failed to replicate these effects.","method":"Acyl-resin assisted capture (acyl-RAC), site-directed mutagenesis, subcellular fractionation (digitonin), pulse-chase protein stability assays, α-synuclein biochemical fractionation, neuronal overexpression","journal":"Science signaling","confidence":"High","confidence_rationale":"Tier 1 / Strong — biochemical palmitoylation mapping, site-directed mutagenesis, multiple orthogonal readouts (localization, stability, α-syn homeostasis) in mouse and human tissue","pmids":["36787382"],"is_preprint":false},{"year":2023,"finding":"Syt11 directly binds endophilin A1 (EndoA1) via a Ca2+-independent interaction (Syt11 C2B domain, aa 314-336 with EndoA1 N-terminus) and inhibits synaptic vesicle endocytosis through EndoA1. Syt11 KO accelerates SV endocytosis and causes abnormal membrane partitioning of synaptic proteins. EndoA1 knockdown reverses the Syt11-KO phenotype. A peptide from Syt11 C2B blocked the interaction in vitro and in vivo and inhibited SV endocytosis at the calyx of Held.","method":"Knockout mice, electrophysiology (capacitance, calyx of Held), Co-IP, in vitro peptide competition assays, EndoA1 knockdown rescue, live imaging","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct binding with domain mapping, peptide competition in vitro and in vivo, genetic epistasis (EndoA1 KD rescue), electrophysiology at physiological temperature","pmids":["37474308"],"is_preprint":false},{"year":2024,"finding":"Syt11 binds both the auxiliary GABAB receptor subunit KCTD16 and Cav2.2 Ca2+ channels, recruiting them to post-Golgi vesicles to facilitate assembly of GBR/Cav2.2 signaling complexes. Syt11 also stabilizes GBRs and Cav2.2 at the neuronal plasma membrane by inhibiting constitutive internalization. Syt11 KO neurons show deficits in presynaptic GBRs and Cav2.2 channels, reduced neurotransmitter release, and decreased GBR-mediated presynaptic inhibition.","method":"Co-immunoprecipitation, co-localization (confocal), knockout mouse neurons, electrophysiology (neurotransmitter release, presynaptic inhibition), internalization assays","journal":"EMBO reports","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP, KO mouse with multiple functional readouts (trafficking, electrophysiology), mechanistic model validated by internalization assay","pmids":["38698221"],"is_preprint":false},{"year":2023,"finding":"In microglia in vivo, Syt11 inhibits microglial activation, cytokine secretion (IL-6, TNF-α, IL-1β, iNOS), and phagocytosis of α-synuclein fibrils. Syt11 directly binds vti1a and vti1b via its linker domain. A competitive peptide from the Syt11 linker domain inhibited vti1a/vti1b interaction in vitro and in cells and induced cytokine hypersecretion in WT microglia upon LPS treatment, phenocopying Syt11 knockdown.","method":"Inducible microglia-specific conditional knockout (cKO) mice, LPS inflammation model, α-synuclein fibril injection model, Co-IP/pull-down, competitive peptide inhibition, cytokine mRNA and protein measurement","journal":"Journal of neurochemistry","confidence":"High","confidence_rationale":"Tier 2 / Strong — inducible conditional KO in vivo, direct binding validated by competitive peptide, multiple in vivo phenotypic readouts","pmids":["37924268"],"is_preprint":false},{"year":2022,"finding":"SYT11 functions as a scaffold protein, binding both MKK7 and JNK1 to promote JNK1 phosphorylation, leading to cJun activation and downstream EMT-related gene expression (ANGPTL2, THBS4, Vimentin, JAM3) in gastric cancer. SYT11 shRNA reduced spheroid formation, tumor growth, and liver metastasis; SYT11-ASO showed antitumor activity in xenograft models.","method":"Phospho-kinase array, co-immunoprecipitation, western blot, shRNA knockdown, xenograft mouse model, liver metastasis assay","journal":"Journal of experimental & clinical cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP confirms MKK7-JNK1-SYT11 complex, in vivo xenograft, phospho-kinase array; single lab","pmids":["35768842"],"is_preprint":false},{"year":2022,"finding":"Impad1 modulates Golgi apparatus morphology and vesicular trafficking through its interaction with Syt11. Inhibiting either Impad1 or Syt11 disrupts the cancer cell secretome and extracellular matrix composition, reversing the invasive/metastatic phenotype of lung cancer cells.","method":"High-throughput in vitro/in vivo screens, co-immunoprecipitation/interaction studies, Golgi morphology imaging, secretome analysis, invasion/metastasis assays","journal":"Cell reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — interaction established by Co-IP, functional epistasis between Impad1 and Syt11 via in vivo screen and Golgi/secretome readouts; single lab","pmids":["36170810"],"is_preprint":false},{"year":2019,"finding":"Syt11 stabilizes caveolar structures on the astrocyte cell surface and regulates caveolae-mediated endocytosis and caveolar responses to mechanical (hypoosmotic) stimuli. Syt11 KO accelerated caveolae-mediated endocytosis and markedly reduced caveolar structures on the cell surface. Syt11 directly interacts with cavin1 and EHD2 (but not caveolin-1) and regulates their turnover, providing a mechanoprotective role.","method":"Knockout astrocytes, live imaging, electron microscopy, Co-IP/pull-down, endocytosis assays, hypoosmotic stimulation, proteasome inhibitor experiments","journal":"FASEB journal","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct interaction established by Co-IP, KO with multiple functional readouts (endocytosis, caveolar structure, mechanosensation); single lab","pmids":["31908017"],"is_preprint":false},{"year":2014,"finding":"Synaptotagmin-11 interacts with components of the RNA-induced silencing complex (RISC) in pancreatic β-cells: the C2A domain interacts with the Q-SNARE Vti1a, while the C2B domain interacts with SND1, Ago2, and FMRP. Binding to SND1 was direct, via SND1's N-terminal tandem repeats.","method":"Co-immunoprecipitation, pull-down, domain deletion constructs (C2A, C2B), MS identification of binding partners","journal":"FEBS letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct binding established by pull-down and Co-IP with domain mapping; single lab, single study","pmids":["24882364"],"is_preprint":false},{"year":2024,"finding":"Syt11 deficiency specifically in dopamine neurons during early adolescence (but not in adults) leads to persistent dopamine over-transmission and schizophrenia-like behaviors (social deficits, etc.) in mice. D2R-targeting interventions (presynaptic or postsynaptic) in the mPFC showed acute and long-lasting therapeutic effects on social deficits.","method":"Conditional knockout (dopamine neuron-specific, adolescent vs. adult), behavioral assays, dopamine transmission measurements, pharmacological rescue with D2R drugs","journal":"Nature communications","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — conditional KO with temporal specificity, pharmacological rescue; single lab, mechanistic pathway placement","pmids":["39632880"],"is_preprint":false},{"year":2020,"finding":"Syt11 is a short-lived protein (half-life ~1.49 h in neurons) primarily degraded by the ubiquitin-proteasome pathway (UPP). Degradation is accelerated under sustained neuronal activity in a parkin-dependent manner. In astrocytes, Syt11 has a faster turnover (half-life ~0.58 h), partially UPP-dependent, but parkin-independent even under hypoosmotic mechanical stress.","method":"Cycloheximide chase assay, proteasome inhibitor (MG132), neuronal activity stimulation, parkin overexpression/knockdown, half-life measurements in neurons and astrocytes","journal":"Neuroscience letters","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct measurement of protein half-life with pharmacological and genetic manipulation; single lab, two cell types compared","pmids":["32976921"],"is_preprint":false},{"year":2007,"finding":"The number of 33-bp repeats in the Syt11 promoter region, which contain an Sp1 binding site, affects Syt11 transcriptional activity. A SNP in the Syt11 5'UTR region, where YY1 can bind, also affects Syt11 transcriptional activity.","method":"Transcriptional reporter (luciferase) assays, gel mobility shift assays (EMSA), polymorphism analysis in schizophrenia patients","journal":"American journal of medical genetics. Part B","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct transcriptional assays and EMSA in single study; functional link to disease candidate but single lab","pmids":["17192956"],"is_preprint":false},{"year":2005,"finding":"Non-CpG methylation in the Syt11 promoter reduces transcriptional activity: methylated cytosines in the coding (minus) strand of the promoter reduce Sp family protein binding (demonstrated by gel mobility shift assay) and decrease reporter gene expression.","method":"Gel mobility shift assay (EMSA), artificially methylated promoter constructs, transient transcription reporter assays","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct biochemical assay (EMSA) and functional reporter assay; single lab, single study","pmids":["15777718"],"is_preprint":false},{"year":2012,"finding":"Syt11 in rat hippocampal neurons is targeted to both dendrite and axon compartments and forms higher molecular weight complexes via its transmembrane domain. Immunogold electron microscopy showed Syt11 predominantly in presynaptic neurotransmitter vesicles and plasma membrane, with rare postsynaptic localization. Both neuroligin-1 and neuroligin-2 recruit Syt11 in neuron co-culture, associating it with excitatory and inhibitory presynapses respectively.","method":"Immunocytochemistry, immunogold electron microscopy, co-culture with neuroligins, SDS-PAGE (higher MW complex detection), subcellular fractionation","journal":"Neuroscience","confidence":"Medium","confidence_rationale":"Tier 2-3 / Moderate — direct subcellular localization by immunogold EM; neuroligin recruitment in coculture; single lab","pmids":["22960622"],"is_preprint":false},{"year":2022,"finding":"In pancreatic β-cells (INS-1 832/13), Syt11 co-localizes with insulin, indicating localization in insulin granules. Knockdown of Syt11 resulted in increased basal and glucose-induced insulin secretion without changes in exocytosis or voltage-gated Ca2+ currents, suggesting a role in suppressing insulin release upstream of final exocytotic steps.","method":"siRNA knockdown, ELISA (insulin secretion), patch-clamp electrophysiology, confocal microscopy co-localization","journal":"Acta physiologica","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — siRNA with functional readout, localization confirmed; single lab, single study","pmids":["35753051"],"is_preprint":false},{"year":2025,"finding":"VHL (an E3 ubiquitin ligase) physically binds SYT11 and promotes its proteasome-dependent degradation without affecting SYT11 mRNA. VHL overexpression decreases SYT11 protein half-life; MG132 (proteasome inhibitor) reverses SYT11 degradation by VHL. VHL knockdown reduces SYT11 ubiquitination. VHL-mediated SYT11 degradation leads to downregulation of SPINK1 and suppression of gastric cancer cell growth and invasion.","method":"Immunoprecipitation, overexpression/knockdown, cycloheximide chase, MG132 proteasome inhibitor, transcriptome sequencing, invasion/growth assays","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP confirms VHL-SYT11 binding, proteasome dependence validated by MG132, ubiquitination assay; single lab","pmids":["40576306"],"is_preprint":false},{"year":2025,"finding":"Compensatory upregulation of Syt11 in parkin knockout mice conceals PD-associated phenotypes: Syt11 is upregulated in parkin KO mice during suckling stage and in adult parkin knockdown (KD) mice. Parkin KD in adult SNpc impairs dopamine release and causes motor deficits (unlike parkin KO). Syt11 overexpression alone induces PD-like motor and non-motor impairments and impairs dopamine release and reuptake, establishing Syt11 accumulation as mechanistically sufficient for parkin-associated PD pathogenesis.","method":"Parkin KO and KD mouse models (viral vector KD in adult SNpc), dopamine release measurements, behavioral assays, Syt11 overexpression, western blot","journal":"Cell communication and signaling","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — genetic and viral KD models compared, Syt11 overexpression sufficiency tested; single lab, single study","pmids":["39901263"],"is_preprint":false}],"current_model":"Synaptotagmin-11 (Syt11) is a calcium-insensitive vesicular trafficking protein that acts as a physiological substrate of parkin (ubiquitin E3 ligase; also regulated by VHL-mediated ubiquitination and proteasomal degradation), residing on post-Golgi/endosomal vesicles where it inhibits endocytosis (by directly binding and suppressing endophilin A1 via its C2B domain), suppresses spontaneous neurotransmission (by binding the non-canonical SNARE vti1a via its C2A domain), facilitates assembly of presynaptic GABAB receptor/Cav2.2 signaling complexes (by scaffolding KCTD16 and Cav2.2), inhibits microglial cytokine secretion and phagocytosis (via vti1a/vti1b interactions), regulates caveolae-mediated endocytosis and mechanosensation in astrocytes (via cavin1 and EHD2), and is palmitoylated at Cys39/Cys40 in a modification that stabilizes it and promotes pathological α-synuclein aggregation, with its accumulation upon parkin loss being the key mediator of dopaminergic neurotoxicity in Parkinson's disease models."},"narrative":{"mechanistic_narrative":"Synaptotagmin-11 (Syt11) is a calcium-insensitive, transmembrane vesicular trafficking protein that resides on post-Golgi/endosomal and recycling vesicles distinct from synaptic vesicles, where it negatively regulates membrane internalization and modulates secretion across neurons, microglia, and astrocytes [PMID:30808661, PMID:28686317]. In neurons Syt11 restrains synaptic vesicle endocytosis and spontaneous transmission through direct, Ca2+-independent interactions: its C2B domain binds and suppresses endophilin A1 to inhibit endocytosis and vesicle pool replenishment [PMID:37474308], while its C2A domain binds the non-canonical SNARE vti1a to suppress spontaneous excitatory release [PMID:34599505]. Syt11 also scaffolds presynaptic signaling by recruiting the GABAB receptor subunit KCTD16 and Cav2.2 channels to post-Golgi vesicles and stabilizing them at the plasma membrane by limiting constitutive internalization, supporting GABAB-mediated presynaptic inhibition and long-term potentiation and memory [PMID:38698221, PMID:30808661]. In microglia Syt11 inhibits activation, cytokine secretion, and phagocytosis of α-synuclein fibrils through binding vti1a/vti1b via its linker domain [PMID:28686317, PMID:37924268], and in astrocytes it stabilizes caveolae and restrains caveolae-mediated endocytosis through interactions with cavin1 and EHD2, conferring mechanoprotection [PMID:31908017]. Syt11 is a short-lived protein degraded by the ubiquitin-proteasome system, and is the physiological substrate of the E3 ligase parkin; loss of parkin causes Syt11 accumulation that is mechanistically sufficient to impair dopamine release and drive late-onset dopaminergic neurodegeneration, identifying Syt11 as a key mediator of Parkinson's disease-like neurotoxicity [PMID:29311685, PMID:39901263, PMID:32976921]. Palmitoylation at Cys39/Cys40 stabilizes Syt11 against endolysosomal degradation and promotes α-synuclein binding to membranes, shifting α-synuclein toward its aggregation-prone monomeric form [PMID:36787382]. Beyond the nervous system, Syt11 acts as a trafficking and scaffolding factor in cancer, binding the MKK7–JNK1 module to promote EMT-related gene expression in gastric cancer [PMID:35768842] and cooperating with Impad1 to control Golgi morphology and the invasive secretome [PMID:36170810].","teleology":[{"year":2005,"claim":"Established that Syt11 transcription is epigenetically and cis-regulated, the first mechanistic handle on how its levels are set before any functional role was known.","evidence":"EMSA and reporter assays with methylated and polymorphic promoter constructs","pmids":["15777718","17192956"],"confidence":"Medium","gaps":["Does not connect promoter regulation to a specific cellular function","Disease association is correlative"]},{"year":2012,"claim":"Resolved where Syt11 acts in neurons, showing it is targeted to presynaptic vesicles and plasma membrane and recruited by neuroligins, placing it at synaptic membranes rather than postsynaptic sites.","evidence":"Immunogold EM, neuroligin co-culture, and fractionation in rat hippocampal neurons","pmids":["22960622"],"confidence":"Medium","gaps":["Functional consequence of synaptic localization not established","Molecular partners mediating vesicle targeting unknown"]},{"year":2014,"claim":"Provided the first domain-level interaction map, distinguishing C2A (vti1a) from C2B (SND1, Ago2, FMRP) binding and linking Syt11 to RISC components in β-cells.","evidence":"Co-IP, pull-down, and domain-deletion constructs in pancreatic β-cells","pmids":["24882364"],"confidence":"Medium","gaps":["Functional role of RISC association not demonstrated","Single-cell-type, single-study evidence"]},{"year":2016,"claim":"Connected Syt11 to lysosomal/autophagic homeostasis by showing ATP13A2 loss lowers Syt11 transcriptionally (via mTORC1/TFEB) and post-translationally, with reduced Syt11 itself causing lysosomal dysfunction.","evidence":"Knockdown, epistasis, transcriptional reporters, ubiquitination and lysosomal assays","pmids":["27278822"],"confidence":"High","gaps":["Direct molecular mechanism by which Syt11 supports lysosomal function not defined","Link to dopaminergic neuron survival not tested here"]},{"year":2017,"claim":"Defined an immune-regulatory function, showing Syt11 suppresses microglial cytokine secretion and phagocytosis and restrains NF-κB, broadening its role beyond neurons.","evidence":"shRNA knockdown with rescue, ELISA, NF-κB reporter, phagocytosis and localization assays in primary microglia","pmids":["28686317"],"confidence":"High","gaps":["Direct binding partner mediating cytokine suppression not yet identified at this stage","In vivo relevance not tested"]},{"year":2018,"claim":"Identified Syt11 as a physiological parkin substrate and showed its accumulation impairs dopamine release and drives dopaminergic degeneration, providing a mechanistic basis for parkin-linked Parkinson's disease.","evidence":"Viral overexpression, knockout mice, dopamine measurements, EM, and genetic rescue in vivo","pmids":["29311685"],"confidence":"High","gaps":["Endocytic effector mediating the dopamine-release defect not yet identified here","Whether endogenous accumulation alone is sufficient not resolved at this stage"]},{"year":2019,"claim":"Characterized Syt11's vesicle identity and core neuronal phenotype, placing it on activity-recycling trafficking endosomes whose loss impairs LTP and memory while sparing fast transmitter release.","evidence":"Constitutive and conditional knockout mice, live imaging, electrophysiology, behavior, fractionation","pmids":["30808661"],"confidence":"High","gaps":["Molecular mechanism of slow desynchronized exocytosis unresolved","Effectors linking the vesicle pool to LTP not defined here"]},{"year":2019,"claim":"Extended Syt11's endocytic-control function to astrocytes, identifying cavin1 and EHD2 as direct partners through which it stabilizes caveolae and provides mechanoprotection.","evidence":"Knockout astrocytes, EM, live imaging, Co-IP, endocytosis and hypoosmotic stimulation assays","pmids":["31908017"],"confidence":"Medium","gaps":["Structural basis of cavin1/EHD2 binding not mapped","Single-lab evidence"]},{"year":2020,"claim":"Quantified Syt11 turnover, establishing it as a short-lived proteasome substrate whose degradation is activity- and parkin-dependent in neurons but parkin-independent in astrocytes.","evidence":"Cycloheximide chase, MG132, activity stimulation, parkin manipulation across neurons and astrocytes","pmids":["32976921"],"confidence":"Medium","gaps":["The non-parkin E3 ligase in astrocytes not identified here","Single-lab study"]},{"year":2021,"claim":"Pinpointed the molecular target for Syt11's suppression of spontaneous release, mapping a high-affinity C2A–vti1a interaction whose disruption reverses the knockout phenotype.","evidence":"KO and overexpression in hippocampal neurons, mEPSC recording, GST pull-down, Co-IP, domain mapping, vti1a knockdown rescue","pmids":["34599505"],"confidence":"High","gaps":["How vti1a binding mechanically suppresses fusion not resolved","Relationship to the endosomal vesicle pool not integrated"]},{"year":2022,"claim":"Revealed non-neural functions of Syt11 as a signaling scaffold (MKK7–JNK1) driving EMT in gastric cancer and as an Impad1 partner controlling Golgi morphology and the invasive secretome.","evidence":"Phospho-kinase array, Co-IP, shRNA, xenograft and metastasis assays; interaction and secretome studies in lung cancer","pmids":["35768842","36170810"],"confidence":"Medium","gaps":["Whether scaffolding and trafficking roles are mechanistically linked unclear","Single-lab evidence for each context"]},{"year":2022,"claim":"Showed Syt11 localizes to insulin granules and suppresses insulin secretion upstream of exocytosis, extending its secretion-braking role to pancreatic β-cells.","evidence":"siRNA knockdown, insulin ELISA, patch-clamp, confocal co-localization in INS-1 cells","pmids":["35753051"],"confidence":"Medium","gaps":["Molecular effector in β-cells not identified","Single-lab, single-study"]},{"year":2023,"claim":"Identified endophilin A1 as the C2B effector through which Syt11 inhibits synaptic vesicle endocytosis, directly linking its trafficking role to the dopamine-release defect seen with accumulation.","evidence":"KO mice, calyx of Held electrophysiology, Co-IP, peptide competition in vitro and in vivo, EndoA1 knockdown rescue","pmids":["37474308"],"confidence":"High","gaps":["Structural model of the C2B–EndoA1 interface not defined","How endocytic braking integrates with vti1a-dependent fusion control unresolved"]},{"year":2023,"claim":"Established a post-translational switch—palmitoylation at Cys39/Cys40—that stabilizes Syt11 and links it to pathological α-synuclein membrane binding and aggregation.","evidence":"Acyl-RAC, site-directed mutagenesis, fractionation, pulse-chase, α-synuclein biochemistry in mouse and human brain","pmids":["36787382"],"confidence":"High","gaps":["Palmitoyltransferase responsible not identified","Causal contribution to in vivo neurodegeneration not directly tested here"]},{"year":2023,"claim":"Confirmed in vivo the microglial immune-suppressive role and mapped its linker-domain binding to vti1a/vti1b, with a competitive peptide phenocopying knockdown.","evidence":"Inducible microglia-specific cKO, LPS and α-synuclein fibril models, Co-IP, competitive peptide inhibition","pmids":["37924268"],"confidence":"High","gaps":["How vti1a/vti1b binding restrains conventional cytokine secretion mechanistically unclear","Interplay with neuronal Syt11 loss in PD not addressed"]},{"year":2024,"claim":"Defined Syt11 as a scaffold assembling presynaptic GABAB receptor/Cav2.2 signaling complexes and stabilizing them at the membrane, providing a mechanism for its support of presynaptic inhibition.","evidence":"Reciprocal Co-IP, co-localization, KO neurons, electrophysiology, internalization assays","pmids":["38698221"],"confidence":"High","gaps":["Binding interfaces for KCTD16 and Cav2.2 not mapped","Relationship between scaffolding and endocytic-braking functions unresolved"]},{"year":2024,"claim":"Demonstrated a developmental-window-specific role, where adolescent dopamine-neuron Syt11 loss produces persistent dopamine over-transmission and schizophrenia-like behavior reversible by D2R-targeted drugs.","evidence":"Temporally controlled dopamine-neuron conditional KO, behavior, dopamine measurements, pharmacological rescue","pmids":["39632880"],"confidence":"Medium","gaps":["Molecular basis of the adolescent-specific requirement unknown","Single-lab study"]},{"year":2025,"claim":"Established Syt11 accumulation as mechanistically sufficient for parkin-associated PD and explained why parkin KO is phenotypically mild via compensatory Syt11 upregulation.","evidence":"Parkin KO and adult viral KD comparison, Syt11 overexpression sufficiency tests, dopamine and behavioral readouts","pmids":["39901263"],"confidence":"Medium","gaps":["Mechanism of developmental Syt11 compensation not defined","Single-lab study"]},{"year":2025,"claim":"Identified VHL as a second E3 ligase that directly binds and proteasomally degrades Syt11, downregulating SPINK1 and suppressing gastric cancer growth, broadening Syt11's degradation control beyond parkin.","evidence":"Co-IP, cycloheximide chase, MG132, ubiquitination assay, transcriptomics, invasion/growth assays","pmids":["40576306"],"confidence":"Medium","gaps":["Whether VHL regulates Syt11 in neurons not tested","Single-lab study"]},{"year":null,"claim":"It remains unknown how Syt11's distinct domain-specific effector interactions (C2A–vti1a, C2B–EndoA1, linker–vti1a/vti1b, scaffolding of KCTD16/Cav2.2) are coordinated on a single vesicle population and how this integration is tuned across neurons, glia, and peripheral cells.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No structural model integrating the multiple binding surfaces","No single study reconciles fusion-suppression and endocytosis-braking roles","Cell-type-specific effector usage not systematically compared"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0060090","term_label":"molecular adaptor activity","supporting_discovery_ids":[4,6,7,11]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,6,7]},{"term_id":"GO:0008289","term_label":"lipid binding","supporting_discovery_ids":[5]}],"localization":[{"term_id":"GO:0031410","term_label":"cytoplasmic vesicle","supporting_discovery_ids":[2,3,7]},{"term_id":"GO:0005794","term_label":"Golgi apparatus","supporting_discovery_ids":[3,10]},{"term_id":"GO:0005768","term_label":"endosome","supporting_discovery_ids":[2,3]},{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[7,11,17]}],"pathway":[{"term_id":"R-HSA-5653656","term_label":"Vesicle-mediated transport","supporting_discovery_ids":[1,2,6,11]},{"term_id":"R-HSA-112316","term_label":"Neuronal System","supporting_discovery_ids":[2,4,7]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[3,8]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[1,9,20]}],"complexes":[],"partners":["VTI1A","SH3GL2","KCTD16","CACNA2/CAV2.2","VTI1B","CAVIN1","EHD2","PARK2/PARKIN"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9BT88","full_name":"Synaptotagmin-11","aliases":["Synaptotagmin XI","SytXI"],"length_aa":431,"mass_kda":48.3,"function":"Synaptotagmin family member involved in vesicular and membrane trafficking which does not bind Ca(2+). Inhibits clathrin-mediated and bulk endocytosis, functions to ensure precision in vesicle retrieval. Plays an important role in dopamine transmission by regulating endocytosis and the vesicle-recycling process. Essential component of a neuronal vesicular trafficking pathway that differs from the synaptic vesicle trafficking pathway but is crucial for development and synaptic plasticity. In macrophages and microglia, inhibits the conventional cytokine secretion, of at least IL6 and TNF, and phagocytosis. In astrocytes, regulates lysosome exocytosis, mechanism required for the repair of injured astrocyte cell membrane (By similarity). Required for the ATP13A2-mediated regulation of the autophagy-lysosome pathway (PubMed:27278822)","subcellular_location":"Cytoplasmic vesicle membrane; Perikaryon; Golgi apparatus, trans-Golgi network membrane; Recycling endosome membrane; Lysosome membrane; Cytoplasmic vesicle, phagosome; Cell projection, axon; Cell projection, dendrite; Postsynaptic density; Recycling endosome membrane; Cytoplasmic vesicle, clathrin-coated vesicle membrane; Perikaryon","url":"https://www.uniprot.org/uniprotkb/Q9BT88/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SYT11","classification":"Not Classified","n_dependent_lines":17,"n_total_lines":1208,"dependency_fraction":0.014072847682119206},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/SYT11","total_profiled":1310},"omim":[{"mim_id":"608741","title":"SYNAPTOTAGMIN 11; SYT11","url":"https://www.omim.org/entry/608741"},{"mim_id":"606436","title":"SYNAPTOTAGMIN 12; SYT12","url":"https://www.omim.org/entry/606436"},{"mim_id":"602544","title":"PARKIN RBR E3 UBIQUITIN PROTEIN LIGASE; PRKN","url":"https://www.omim.org/entry/602544"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in all","driving_tissues":[{"tissue":"brain","ntpm":227.7}],"url":"https://www.proteinatlas.org/search/SYT11"},"hgnc":{"alias_symbol":["KIAA0080","MGC10881","MGC17226","DKFZp781D015"],"prev_symbol":[]},"alphafold":{"accession":"Q9BT88","domains":[{"cath_id":"2.60.40.150","chopping":"160-282","consensus_level":"high","plddt":91.9118,"start":160,"end":282},{"cath_id":"2.60.40.150","chopping":"295-428","consensus_level":"high","plddt":92.464,"start":295,"end":428}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BT88","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BT88-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9BT88-F1-predicted_aligned_error_v6.png","plddt_mean":75.5},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SYT11","jax_strain_url":"https://www.jax.org/strain/search?query=SYT11"},"sequence":{"accession":"Q9BT88","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9BT88.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9BT88/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9BT88"}},"corpus_meta":[{"pmid":"27278822","id":"PMC_27278822","title":"The Parkinson's disease-associated genes ATP13A2 and SYT11 regulate autophagy via a common pathway.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27278822","citation_count":159,"is_preprint":false},{"pmid":"21812969","id":"PMC_21812969","title":"Genome-wide association study identifies candidate genes for Parkinson's disease in an Ashkenazi Jewish population.","date":"2011","source":"BMC medical genetics","url":"https://pubmed.ncbi.nlm.nih.gov/21812969","citation_count":137,"is_preprint":false},{"pmid":"7584044","id":"PMC_7584044","title":"Prediction of the coding sequences of unidentified human genes. II. The coding sequences of 40 new genes (KIAA0041-KIAA0080) deduced by analysis of cDNA clones from human cell line KG-1.","date":"1994","source":"DNA research : an international journal for rapid publication of reports on genes and genomes","url":"https://pubmed.ncbi.nlm.nih.gov/7584044","citation_count":122,"is_preprint":false},{"pmid":"34729301","id":"PMC_34729301","title":"Targeting autophagy using small-molecule compounds to improve potential therapy of Parkinson's disease.","date":"2021","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/34729301","citation_count":117,"is_preprint":false},{"pmid":"22939844","id":"PMC_22939844","title":"Reduced insulin secretion correlates with decreased expression of exocytotic genes in pancreatic islets from patients with type 2 diabetes.","date":"2012","source":"Molecular and cellular endocrinology","url":"https://pubmed.ncbi.nlm.nih.gov/22939844","citation_count":107,"is_preprint":false},{"pmid":"29311685","id":"PMC_29311685","title":"Synaptotagmin-11 is a critical mediator of parkin-linked neurotoxicity and Parkinson's disease-like pathology.","date":"2018","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/29311685","citation_count":88,"is_preprint":false},{"pmid":"19030179","id":"PMC_19030179","title":"Differential mRNA expression patterns of the synaptotagmin gene family in the rodent brain.","date":"2009","source":"The Journal of comparative neurology","url":"https://pubmed.ncbi.nlm.nih.gov/19030179","citation_count":70,"is_preprint":false},{"pmid":"30808661","id":"PMC_30808661","title":"Synaptotagmin-11 mediates a vesicle trafficking pathway that is essential for development and synaptic plasticity.","date":"2019","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/30808661","citation_count":59,"is_preprint":false},{"pmid":"25393317","id":"PMC_25393317","title":"Mammalian Non-CpG Methylation: Stem Cells and Beyond.","date":"2014","source":"Biology","url":"https://pubmed.ncbi.nlm.nih.gov/25393317","citation_count":56,"is_preprint":false},{"pmid":"18937310","id":"PMC_18937310","title":"A comparison of molecular alterations in environmental and genetic rat models of ADHD: a pilot study.","date":"2008","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/18937310","citation_count":54,"is_preprint":false},{"pmid":"28830825","id":"PMC_28830825","title":"The GBA variant E326K is associated with Parkinson's disease and explains a genome-wide association signal.","date":"2017","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/28830825","citation_count":50,"is_preprint":false},{"pmid":"33349842","id":"PMC_33349842","title":"Targeted sequencing of Parkinson's disease loci genes highlights SYT11, FGF20 and other associations.","date":"2021","source":"Brain : a journal of neurology","url":"https://pubmed.ncbi.nlm.nih.gov/33349842","citation_count":48,"is_preprint":false},{"pmid":"28686317","id":"PMC_28686317","title":"Synaptotagmin-11 inhibits cytokine secretion and phagocytosis in microglia.","date":"2017","source":"Glia","url":"https://pubmed.ncbi.nlm.nih.gov/28686317","citation_count":35,"is_preprint":false},{"pmid":"28348516","id":"PMC_28348516","title":"Molecular Mechanisms for the Coupling of Endocytosis to Exocytosis in Neurons.","date":"2017","source":"Frontiers in molecular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/28348516","citation_count":35,"is_preprint":false},{"pmid":"21734494","id":"PMC_21734494","title":"Genetics of Parkinson's disease and essential tremor.","date":"2011","source":"Current opinion in neurology","url":"https://pubmed.ncbi.nlm.nih.gov/21734494","citation_count":35,"is_preprint":false},{"pmid":"17192956","id":"PMC_17192956","title":"Synaptotagmin XI as a candidate gene for susceptibility to schizophrenia.","date":"2007","source":"American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics","url":"https://pubmed.ncbi.nlm.nih.gov/17192956","citation_count":34,"is_preprint":false},{"pmid":"27393345","id":"PMC_27393345","title":"Genome-wide assessment of Parkinson's disease in a Southern Spanish population.","date":"2016","source":"Neurobiology of aging","url":"https://pubmed.ncbi.nlm.nih.gov/27393345","citation_count":33,"is_preprint":false},{"pmid":"36787382","id":"PMC_36787382","title":"Palmitoylation of the Parkinson's disease-associated protein synaptotagmin-11 links its turnover to α-synuclein homeostasis.","date":"2023","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/36787382","citation_count":31,"is_preprint":false},{"pmid":"15777718","id":"PMC_15777718","title":"Effects of methylation of non-CpG sequence in the promoter region on the expression of human synaptotagmin XI (syt11).","date":"2005","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/15777718","citation_count":30,"is_preprint":false},{"pmid":"32006661","id":"PMC_32006661","title":"Schizophrenia-associated MicroRNA-Gene Interactions in the Dorsolateral Prefrontal Cortex.","date":"2020","source":"Genomics, proteomics & bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/32006661","citation_count":27,"is_preprint":false},{"pmid":"29122960","id":"PMC_29122960","title":"MiR-335 overexpression impairs insulin secretion through defective priming of insulin vesicles.","date":"2017","source":"Physiological reports","url":"https://pubmed.ncbi.nlm.nih.gov/29122960","citation_count":27,"is_preprint":false},{"pmid":"37212950","id":"PMC_37212950","title":"Novel Drug Targets for Atrial Fibrillation Identified Through Mendelian Randomization Analysis of the Blood Proteome.","date":"2023","source":"Cardiovascular drugs and therapy","url":"https://pubmed.ncbi.nlm.nih.gov/37212950","citation_count":25,"is_preprint":false},{"pmid":"29186589","id":"PMC_29186589","title":"Detergent Insoluble Proteins and Inclusion Body-Like Structures Immunoreactive for PRKDC/DNA-PK/DNA-PKcs, FTL, NNT, and AIFM1 in the Amygdala of Cognitively Impaired Elderly Persons.","date":"2018","source":"Journal of neuropathology and experimental neurology","url":"https://pubmed.ncbi.nlm.nih.gov/29186589","citation_count":22,"is_preprint":false},{"pmid":"30194076","id":"PMC_30194076","title":"Whole-transcriptomic Profile of SK-MEL-3 Melanoma Cells Treated with the Histone Deacetylase Inhibitor: Trichostatin A.","date":"2018","source":"Cancer genomics & proteomics","url":"https://pubmed.ncbi.nlm.nih.gov/30194076","citation_count":21,"is_preprint":false},{"pmid":"24882364","id":"PMC_24882364","title":"Synaptotagmin 11 interacts with components of the RNA-induced silencing complex RISC in clonal pancreatic β-cells.","date":"2014","source":"FEBS letters","url":"https://pubmed.ncbi.nlm.nih.gov/24882364","citation_count":20,"is_preprint":false},{"pmid":"20470891","id":"PMC_20470891","title":"Developmental expression of Synaptotagmin isoforms in single calyx of Held-generating neurons.","date":"2010","source":"Molecular and cellular neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/20470891","citation_count":19,"is_preprint":false},{"pmid":"35768842","id":"PMC_35768842","title":"Synaptotagmin 11 scaffolds MKK7-JNK signaling process to promote stem-like molecular subtype gastric cancer oncogenesis.","date":"2022","source":"Journal of experimental & clinical cancer research : CR","url":"https://pubmed.ncbi.nlm.nih.gov/35768842","citation_count":18,"is_preprint":false},{"pmid":"34702310","id":"PMC_34702310","title":"Identification and drug-induced reversion of molecular signatures of Alzheimer's disease onset and progression in AppNL-G-F, AppNL-F, and 3xTg-AD mouse models.","date":"2021","source":"Genome medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34702310","citation_count":18,"is_preprint":false},{"pmid":"35753051","id":"PMC_35753051","title":"The highly expressed calcium-insensitive synaptotagmin-11 and synaptotagmin-13 modulate insulin secretion.","date":"2022","source":"Acta physiologica (Oxford, England)","url":"https://pubmed.ncbi.nlm.nih.gov/35753051","citation_count":14,"is_preprint":false},{"pmid":"39632880","id":"PMC_39632880","title":"Synaptotagmin-11 deficiency mediates schizophrenia-like behaviors in mice via dopamine over-transmission.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/39632880","citation_count":12,"is_preprint":false},{"pmid":"29300844","id":"PMC_29300844","title":"Link synthetic lethality to drug sensitivity of cancer cells.","date":"2019","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/29300844","citation_count":12,"is_preprint":false},{"pmid":"23916622","id":"PMC_23916622","title":"Meta-analysis supports association of a functional SNP (rs1801133) in the MTHFR gene with Parkinson's disease.","date":"2013","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/23916622","citation_count":12,"is_preprint":false},{"pmid":"34599505","id":"PMC_34599505","title":"Synaptotagmin-11 inhibits spontaneous neurotransmission through vti1a.","date":"2021","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/34599505","citation_count":11,"is_preprint":false},{"pmid":"35728661","id":"PMC_35728661","title":"miR-146a/KLF4 axis in epileptic mice: A novel regulator of synaptic plasticity involving STAT3 signaling.","date":"2022","source":"Brain research","url":"https://pubmed.ncbi.nlm.nih.gov/35728661","citation_count":11,"is_preprint":false},{"pmid":"36170810","id":"PMC_36170810","title":"Impad1 and Syt11 work in an epistatic pathway that regulates EMT-mediated vesicular trafficking to drive lung cancer invasion and metastasis.","date":"2022","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/36170810","citation_count":10,"is_preprint":false},{"pmid":"31908017","id":"PMC_31908017","title":"Synaptotagmin-11 regulates the functions of caveolae and responds to mechanical stimuli in astrocytes.","date":"2019","source":"FASEB journal : official publication of the Federation of American Societies for Experimental Biology","url":"https://pubmed.ncbi.nlm.nih.gov/31908017","citation_count":10,"is_preprint":false},{"pmid":"36960065","id":"PMC_36960065","title":"Tumor-associated macrophages respond to chemotherapy by detrimental transcriptional reprogramming and suppressing stabilin-1 mediated clearance of EGF.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36960065","citation_count":10,"is_preprint":false},{"pmid":"22960622","id":"PMC_22960622","title":"Developmental expression and subcellular distribution of synaptotagmin 11 in rat hippocampus.","date":"2012","source":"Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/22960622","citation_count":9,"is_preprint":false},{"pmid":"24631562","id":"PMC_24631562","title":"Association analysis of STK39, MCCC1/LAMP3 and sporadic PD in the Chinese Han population.","date":"2014","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/24631562","citation_count":8,"is_preprint":false},{"pmid":"35205089","id":"PMC_35205089","title":"Distribution of Copy Number Variation in SYT11 Gene and Its Association with Growth Conformation Traits in Chinese Cattle.","date":"2022","source":"Biology","url":"https://pubmed.ncbi.nlm.nih.gov/35205089","citation_count":6,"is_preprint":false},{"pmid":"38698221","id":"PMC_38698221","title":"Synaptotagmin-11 facilitates assembly of a presynaptic signaling complex in post-Golgi cargo vesicles.","date":"2024","source":"EMBO reports","url":"https://pubmed.ncbi.nlm.nih.gov/38698221","citation_count":6,"is_preprint":false},{"pmid":"37474308","id":"PMC_37474308","title":"Synaptotagmin-11 Inhibits Synaptic Vesicle Endocytosis via Endophilin A1.","date":"2023","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/37474308","citation_count":6,"is_preprint":false},{"pmid":"37924268","id":"PMC_37924268","title":"Synaptotagmin-11 regulates immune functions of microglia in vivo.","date":"2023","source":"Journal of neurochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37924268","citation_count":5,"is_preprint":false},{"pmid":"32976921","id":"PMC_32976921","title":"Parkin-dependent and -independent degradation of synaptotagmin-11 in neurons and astrocytes.","date":"2020","source":"Neuroscience letters","url":"https://pubmed.ncbi.nlm.nih.gov/32976921","citation_count":4,"is_preprint":false},{"pmid":"40631452","id":"PMC_40631452","title":"Comprehensive characterization of the RNA editing landscape in the human aging brains with Alzheimer's disease.","date":"2025","source":"Alzheimer's & dementia : the journal of the Alzheimer's Association","url":"https://pubmed.ncbi.nlm.nih.gov/40631452","citation_count":4,"is_preprint":false},{"pmid":"41254737","id":"PMC_41254737","title":"Plasma proteins and onset of atherosclerosis: integrating human plasma proteogenomics, transcriptomics and in vivo evidence.","date":"2025","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41254737","citation_count":3,"is_preprint":false},{"pmid":"40017568","id":"PMC_40017568","title":"From Diagnosis to Treatment: A Comprehensive Review of Biomarkers and Therapeutic Advances in Parkinson's Disease.","date":"2023","source":"Annals of neurosciences","url":"https://pubmed.ncbi.nlm.nih.gov/40017568","citation_count":3,"is_preprint":false},{"pmid":"38766439","id":"PMC_38766439","title":"Synaptotagmins family affect glucose transport in retinal pigment epithelial cells through their ubiquitination-mediated degradation and glucose transporter-1 regulation.","date":"2024","source":"World journal of diabetes","url":"https://pubmed.ncbi.nlm.nih.gov/38766439","citation_count":3,"is_preprint":false},{"pmid":"40101577","id":"PMC_40101577","title":"In vitro and in vivo antidiabetic evaluation of new Coumarin and Chromone derivatives: Design, synthesis and molecular modeling.","date":"2025","source":"Bioorganic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/40101577","citation_count":3,"is_preprint":false},{"pmid":"39901263","id":"PMC_39901263","title":"Compensatory synaptotagmin-11 expression conceals parkinson's disease-like phenotypes in parkin knockout mice.","date":"2025","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/39901263","citation_count":2,"is_preprint":false},{"pmid":"39959641","id":"PMC_39959641","title":"Inflammatory Gene Signature Identified by Machine Algorithms Reveals Novel Biomarkers of Coronary Artery Disease.","date":"2025","source":"Journal of inflammation research","url":"https://pubmed.ncbi.nlm.nih.gov/39959641","citation_count":2,"is_preprint":false},{"pmid":"40576306","id":"PMC_40576306","title":"VHL-Mediated SYT11 Degradation Suppresses Gastric Cancer Cell Growth and Invasion Through Downregulation of SPINK1.","date":"2025","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40576306","citation_count":1,"is_preprint":false},{"pmid":"32253955","id":"PMC_32253955","title":"The rs3129882/rs4248166 in HLA-DRA and rs34372695 in SYT11 are not associated with sporadic Parkinson's disease in Central Chinese population.","date":"2020","source":"The International journal of neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32253955","citation_count":1,"is_preprint":false},{"pmid":"38890718","id":"PMC_38890718","title":"Role of SYT11 in human pan-cancer using comprehensive approaches.","date":"2024","source":"European journal of medical research","url":"https://pubmed.ncbi.nlm.nih.gov/38890718","citation_count":1,"is_preprint":false},{"pmid":"40755781","id":"PMC_40755781","title":"To reveal biomarkers related to macrophage and lactic acid metabolism in renal fibrosis and explore their mechanisms.","date":"2025","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/40755781","citation_count":1,"is_preprint":false},{"pmid":"41798285","id":"PMC_41798285","title":"The genetic architecture of Parkinson's disease in Mexico: a systematic review.","date":"2026","source":"Frontiers in aging neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/41798285","citation_count":0,"is_preprint":false},{"pmid":"40676322","id":"PMC_40676322","title":"Ca2+-Affinitive and Non-Ca2+-Affinitive Synaptotagmins in Human Pan-cancer.","date":"2025","source":"Neuromolecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40676322","citation_count":0,"is_preprint":false},{"pmid":"40703511","id":"PMC_40703511","title":"Protein regulatory network mediated by palmitoylation modifications in the pathological progression of Parkinson's disease: a narrative review.","date":"2025","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/40703511","citation_count":0,"is_preprint":false},{"pmid":"41367007","id":"PMC_41367007","title":"Identification of breast cancer susceptibility genes via trans-ethnic Mendelian randomization and colocalization analyses.","date":"2025","source":"Medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41367007","citation_count":0,"is_preprint":false},{"pmid":"39486179","id":"PMC_39486179","title":"Use of mendelian randomization to assess the causal associations of circulating plasma proteins with 12-lead ECG parameters.","date":"2024","source":"International immunopharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39486179","citation_count":0,"is_preprint":false},{"pmid":"33807234","id":"PMC_33807234","title":"De Novo 1q21.3q22 Duplication Revaluation in a \"Cold\" Complex Neuropsychiatric Case with Syndromic Intellectual Disability.","date":"2021","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/33807234","citation_count":0,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":34623,"output_tokens":6136,"usd":0.097954,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":14741,"output_tokens":5831,"usd":0.10974,"stage2_stop_reason":"end_turn"},"total_usd":0.207694,"stage1_batch_id":"msgbatch_017qqVz33Ga63SCDwzb35XPb","stage2_batch_id":"msgbatch_01Scr2Ei9x4HJMiRGxwrmvLK","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2016,\n      \"finding\": \"ATP13A2 depletion negatively regulates SYT11 at both transcriptional and post-translational levels: decreased SYT11 transcription is controlled by MYCBP2-induced ubiquitination of TSC2, leading to mTORC1 activation and decreased TFEB-mediated transcription of SYT11, while increased protein turnover is regulated by SYT11 ubiquitination and degradation. Decreased SYT11 levels in turn induce lysosomal dysfunction and impaired degradation of autophagosomes.\",\n      \"method\": \"Genetic knockdown, epistasis analysis, transcriptional reporter assays, ubiquitination assays, lysosomal function assays\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (knockdown, epistasis, ubiquitination, lysosomal function assays) in a single study, replicated across conditions\",\n      \"pmids\": [\"27278822\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Synaptotagmin-11 is a physiological substrate of parkin (E3 ubiquitin ligase). Parkin deficiency leads to synaptotagmin-11 accumulation. Unilateral overexpression of full-length (but not C2B-truncated) synaptotagmin-11 in the substantia nigra pars compacta impairs striatal dopamine release by inhibiting endocytosis and vesicle pool replenishment, causing late-onset dopaminergic neuron degeneration and progressive motor abnormalities. SYT11 knockdown or knockout in dopaminergic neurons reversed parkin-deficiency-induced PD-like neurotoxicity.\",\n      \"method\": \"In vivo overexpression (viral vector), knockout mice, dopamine release measurements, electron microscopy, genetic rescue experiments\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal in vivo methods (overexpression, knockout, rescue), mechanistic dissection with truncation mutant, replicated across models\",\n      \"pmids\": [\"29311685\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"In neurons, Syt11 resides on abundant vesicles resembling trafficking endosomes (distinct from synaptic vesicles) that recycle via the plasma membrane in an activity-dependent manner with slow, desynchronized exocytosis. Constitutive Syt11 knockout mice die shortly after birth. Conditional knockout of Syt11 in excitatory forebrain neurons impairs long-term synaptic potentiation and memory without affecting fast neurotransmitter or peptide secretion.\",\n      \"method\": \"Conditional and constitutive knockout mice, live-cell imaging, electrophysiology, memory behavioral assays, vesicle fractionation\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — constitutive and conditional knockout models with multiple orthogonal phenotypic readouts, live imaging for localization\",\n      \"pmids\": [\"30808661\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Syt11 inhibits cytokine secretion and phagocytosis in microglia. Syt11 knockdown increases IL-6, TNF-α, IL-1β, and iNOS synthesis and activates NF-κB. Syt11 specifically regulates conventional secretion of IL-6 and TNF-α. Syt11 localizes to the trans-Golgi network and recycling endosomes and is recruited to phagosomes. Syt11 deficiency enhances phagocytosis including that of α-synuclein fibrils. All KD phenotypes were rescued by shRNA-resistant Syt11.\",\n      \"method\": \"shRNA knockdown in primary microglia, overexpression rescue, ELISA, NF-κB reporter, immunofluorescence/confocal microscopy, phagocytosis assay\",\n      \"journal\": \"Glia\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — knockdown with rescue controls, multiple orthogonal functional readouts (secretion, phagocytosis, signaling), localization experiments\",\n      \"pmids\": [\"28686317\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Syt11 suppresses spontaneous (miniature) excitatory neurotransmission. Syt11-KO hippocampal neurons show increased mEPSC frequency; Syt11 overexpression decreases mEPSC frequency without affecting amplitude, indicating presynaptic regulation. Syt11 directly interacts with the non-canonical SNARE protein vti1a (C2A domain of Syt11 binds vti1a with high affinity), and vti1a knockdown reverses the Syt11-KO phenotype, identifying vti1a as the primary target.\",\n      \"method\": \"Knockout and overexpression in hippocampal neurons, electrophysiology (mEPSC recording), GST pull-down, co-immunoprecipitation, affinity purification, domain deletion analysis\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct binding established by GST pull-down and Co-IP, epistasis by vti1a KD rescue, electrophysiology, domain mapping\",\n      \"pmids\": [\"34599505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Syt11 is palmitoylated at Cys39 and Cys40 (adjacent to its transmembrane domain) in mouse and human brain tissue and cultured neurons. Palmitoylation localizes Syt11 to digitonin-insoluble intracellular membranes and protects it from endolysosomal degradation. Palmitoylated Syt11 increases its own abundance and enhances α-synuclein binding to intracellular membranes, decreasing the physiologic tetrameric form and increasing the aggregation-prone monomeric form. A palmitoylation-deficient mutant failed to replicate these effects.\",\n      \"method\": \"Acyl-resin assisted capture (acyl-RAC), site-directed mutagenesis, subcellular fractionation (digitonin), pulse-chase protein stability assays, α-synuclein biochemical fractionation, neuronal overexpression\",\n      \"journal\": \"Science signaling\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Strong — biochemical palmitoylation mapping, site-directed mutagenesis, multiple orthogonal readouts (localization, stability, α-syn homeostasis) in mouse and human tissue\",\n      \"pmids\": [\"36787382\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Syt11 directly binds endophilin A1 (EndoA1) via a Ca2+-independent interaction (Syt11 C2B domain, aa 314-336 with EndoA1 N-terminus) and inhibits synaptic vesicle endocytosis through EndoA1. Syt11 KO accelerates SV endocytosis and causes abnormal membrane partitioning of synaptic proteins. EndoA1 knockdown reverses the Syt11-KO phenotype. A peptide from Syt11 C2B blocked the interaction in vitro and in vivo and inhibited SV endocytosis at the calyx of Held.\",\n      \"method\": \"Knockout mice, electrophysiology (capacitance, calyx of Held), Co-IP, in vitro peptide competition assays, EndoA1 knockdown rescue, live imaging\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct binding with domain mapping, peptide competition in vitro and in vivo, genetic epistasis (EndoA1 KD rescue), electrophysiology at physiological temperature\",\n      \"pmids\": [\"37474308\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Syt11 binds both the auxiliary GABAB receptor subunit KCTD16 and Cav2.2 Ca2+ channels, recruiting them to post-Golgi vesicles to facilitate assembly of GBR/Cav2.2 signaling complexes. Syt11 also stabilizes GBRs and Cav2.2 at the neuronal plasma membrane by inhibiting constitutive internalization. Syt11 KO neurons show deficits in presynaptic GBRs and Cav2.2 channels, reduced neurotransmitter release, and decreased GBR-mediated presynaptic inhibition.\",\n      \"method\": \"Co-immunoprecipitation, co-localization (confocal), knockout mouse neurons, electrophysiology (neurotransmitter release, presynaptic inhibition), internalization assays\",\n      \"journal\": \"EMBO reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP, KO mouse with multiple functional readouts (trafficking, electrophysiology), mechanistic model validated by internalization assay\",\n      \"pmids\": [\"38698221\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"In microglia in vivo, Syt11 inhibits microglial activation, cytokine secretion (IL-6, TNF-α, IL-1β, iNOS), and phagocytosis of α-synuclein fibrils. Syt11 directly binds vti1a and vti1b via its linker domain. A competitive peptide from the Syt11 linker domain inhibited vti1a/vti1b interaction in vitro and in cells and induced cytokine hypersecretion in WT microglia upon LPS treatment, phenocopying Syt11 knockdown.\",\n      \"method\": \"Inducible microglia-specific conditional knockout (cKO) mice, LPS inflammation model, α-synuclein fibril injection model, Co-IP/pull-down, competitive peptide inhibition, cytokine mRNA and protein measurement\",\n      \"journal\": \"Journal of neurochemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — inducible conditional KO in vivo, direct binding validated by competitive peptide, multiple in vivo phenotypic readouts\",\n      \"pmids\": [\"37924268\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SYT11 functions as a scaffold protein, binding both MKK7 and JNK1 to promote JNK1 phosphorylation, leading to cJun activation and downstream EMT-related gene expression (ANGPTL2, THBS4, Vimentin, JAM3) in gastric cancer. SYT11 shRNA reduced spheroid formation, tumor growth, and liver metastasis; SYT11-ASO showed antitumor activity in xenograft models.\",\n      \"method\": \"Phospho-kinase array, co-immunoprecipitation, western blot, shRNA knockdown, xenograft mouse model, liver metastasis assay\",\n      \"journal\": \"Journal of experimental & clinical cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP confirms MKK7-JNK1-SYT11 complex, in vivo xenograft, phospho-kinase array; single lab\",\n      \"pmids\": [\"35768842\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Impad1 modulates Golgi apparatus morphology and vesicular trafficking through its interaction with Syt11. Inhibiting either Impad1 or Syt11 disrupts the cancer cell secretome and extracellular matrix composition, reversing the invasive/metastatic phenotype of lung cancer cells.\",\n      \"method\": \"High-throughput in vitro/in vivo screens, co-immunoprecipitation/interaction studies, Golgi morphology imaging, secretome analysis, invasion/metastasis assays\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — interaction established by Co-IP, functional epistasis between Impad1 and Syt11 via in vivo screen and Golgi/secretome readouts; single lab\",\n      \"pmids\": [\"36170810\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Syt11 stabilizes caveolar structures on the astrocyte cell surface and regulates caveolae-mediated endocytosis and caveolar responses to mechanical (hypoosmotic) stimuli. Syt11 KO accelerated caveolae-mediated endocytosis and markedly reduced caveolar structures on the cell surface. Syt11 directly interacts with cavin1 and EHD2 (but not caveolin-1) and regulates their turnover, providing a mechanoprotective role.\",\n      \"method\": \"Knockout astrocytes, live imaging, electron microscopy, Co-IP/pull-down, endocytosis assays, hypoosmotic stimulation, proteasome inhibitor experiments\",\n      \"journal\": \"FASEB journal\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct interaction established by Co-IP, KO with multiple functional readouts (endocytosis, caveolar structure, mechanosensation); single lab\",\n      \"pmids\": [\"31908017\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Synaptotagmin-11 interacts with components of the RNA-induced silencing complex (RISC) in pancreatic β-cells: the C2A domain interacts with the Q-SNARE Vti1a, while the C2B domain interacts with SND1, Ago2, and FMRP. Binding to SND1 was direct, via SND1's N-terminal tandem repeats.\",\n      \"method\": \"Co-immunoprecipitation, pull-down, domain deletion constructs (C2A, C2B), MS identification of binding partners\",\n      \"journal\": \"FEBS letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct binding established by pull-down and Co-IP with domain mapping; single lab, single study\",\n      \"pmids\": [\"24882364\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Syt11 deficiency specifically in dopamine neurons during early adolescence (but not in adults) leads to persistent dopamine over-transmission and schizophrenia-like behaviors (social deficits, etc.) in mice. D2R-targeting interventions (presynaptic or postsynaptic) in the mPFC showed acute and long-lasting therapeutic effects on social deficits.\",\n      \"method\": \"Conditional knockout (dopamine neuron-specific, adolescent vs. adult), behavioral assays, dopamine transmission measurements, pharmacological rescue with D2R drugs\",\n      \"journal\": \"Nature communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — conditional KO with temporal specificity, pharmacological rescue; single lab, mechanistic pathway placement\",\n      \"pmids\": [\"39632880\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Syt11 is a short-lived protein (half-life ~1.49 h in neurons) primarily degraded by the ubiquitin-proteasome pathway (UPP). Degradation is accelerated under sustained neuronal activity in a parkin-dependent manner. In astrocytes, Syt11 has a faster turnover (half-life ~0.58 h), partially UPP-dependent, but parkin-independent even under hypoosmotic mechanical stress.\",\n      \"method\": \"Cycloheximide chase assay, proteasome inhibitor (MG132), neuronal activity stimulation, parkin overexpression/knockdown, half-life measurements in neurons and astrocytes\",\n      \"journal\": \"Neuroscience letters\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct measurement of protein half-life with pharmacological and genetic manipulation; single lab, two cell types compared\",\n      \"pmids\": [\"32976921\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"The number of 33-bp repeats in the Syt11 promoter region, which contain an Sp1 binding site, affects Syt11 transcriptional activity. A SNP in the Syt11 5'UTR region, where YY1 can bind, also affects Syt11 transcriptional activity.\",\n      \"method\": \"Transcriptional reporter (luciferase) assays, gel mobility shift assays (EMSA), polymorphism analysis in schizophrenia patients\",\n      \"journal\": \"American journal of medical genetics. Part B\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct transcriptional assays and EMSA in single study; functional link to disease candidate but single lab\",\n      \"pmids\": [\"17192956\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Non-CpG methylation in the Syt11 promoter reduces transcriptional activity: methylated cytosines in the coding (minus) strand of the promoter reduce Sp family protein binding (demonstrated by gel mobility shift assay) and decrease reporter gene expression.\",\n      \"method\": \"Gel mobility shift assay (EMSA), artificially methylated promoter constructs, transient transcription reporter assays\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct biochemical assay (EMSA) and functional reporter assay; single lab, single study\",\n      \"pmids\": [\"15777718\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"Syt11 in rat hippocampal neurons is targeted to both dendrite and axon compartments and forms higher molecular weight complexes via its transmembrane domain. Immunogold electron microscopy showed Syt11 predominantly in presynaptic neurotransmitter vesicles and plasma membrane, with rare postsynaptic localization. Both neuroligin-1 and neuroligin-2 recruit Syt11 in neuron co-culture, associating it with excitatory and inhibitory presynapses respectively.\",\n      \"method\": \"Immunocytochemistry, immunogold electron microscopy, co-culture with neuroligins, SDS-PAGE (higher MW complex detection), subcellular fractionation\",\n      \"journal\": \"Neuroscience\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 / Moderate — direct subcellular localization by immunogold EM; neuroligin recruitment in coculture; single lab\",\n      \"pmids\": [\"22960622\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"In pancreatic β-cells (INS-1 832/13), Syt11 co-localizes with insulin, indicating localization in insulin granules. Knockdown of Syt11 resulted in increased basal and glucose-induced insulin secretion without changes in exocytosis or voltage-gated Ca2+ currents, suggesting a role in suppressing insulin release upstream of final exocytotic steps.\",\n      \"method\": \"siRNA knockdown, ELISA (insulin secretion), patch-clamp electrophysiology, confocal microscopy co-localization\",\n      \"journal\": \"Acta physiologica\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — siRNA with functional readout, localization confirmed; single lab, single study\",\n      \"pmids\": [\"35753051\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"VHL (an E3 ubiquitin ligase) physically binds SYT11 and promotes its proteasome-dependent degradation without affecting SYT11 mRNA. VHL overexpression decreases SYT11 protein half-life; MG132 (proteasome inhibitor) reverses SYT11 degradation by VHL. VHL knockdown reduces SYT11 ubiquitination. VHL-mediated SYT11 degradation leads to downregulation of SPINK1 and suppression of gastric cancer cell growth and invasion.\",\n      \"method\": \"Immunoprecipitation, overexpression/knockdown, cycloheximide chase, MG132 proteasome inhibitor, transcriptome sequencing, invasion/growth assays\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP confirms VHL-SYT11 binding, proteasome dependence validated by MG132, ubiquitination assay; single lab\",\n      \"pmids\": [\"40576306\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Compensatory upregulation of Syt11 in parkin knockout mice conceals PD-associated phenotypes: Syt11 is upregulated in parkin KO mice during suckling stage and in adult parkin knockdown (KD) mice. Parkin KD in adult SNpc impairs dopamine release and causes motor deficits (unlike parkin KO). Syt11 overexpression alone induces PD-like motor and non-motor impairments and impairs dopamine release and reuptake, establishing Syt11 accumulation as mechanistically sufficient for parkin-associated PD pathogenesis.\",\n      \"method\": \"Parkin KO and KD mouse models (viral vector KD in adult SNpc), dopamine release measurements, behavioral assays, Syt11 overexpression, western blot\",\n      \"journal\": \"Cell communication and signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — genetic and viral KD models compared, Syt11 overexpression sufficiency tested; single lab, single study\",\n      \"pmids\": [\"39901263\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"Synaptotagmin-11 (Syt11) is a calcium-insensitive vesicular trafficking protein that acts as a physiological substrate of parkin (ubiquitin E3 ligase; also regulated by VHL-mediated ubiquitination and proteasomal degradation), residing on post-Golgi/endosomal vesicles where it inhibits endocytosis (by directly binding and suppressing endophilin A1 via its C2B domain), suppresses spontaneous neurotransmission (by binding the non-canonical SNARE vti1a via its C2A domain), facilitates assembly of presynaptic GABAB receptor/Cav2.2 signaling complexes (by scaffolding KCTD16 and Cav2.2), inhibits microglial cytokine secretion and phagocytosis (via vti1a/vti1b interactions), regulates caveolae-mediated endocytosis and mechanosensation in astrocytes (via cavin1 and EHD2), and is palmitoylated at Cys39/Cys40 in a modification that stabilizes it and promotes pathological α-synuclein aggregation, with its accumulation upon parkin loss being the key mediator of dopaminergic neurotoxicity in Parkinson's disease models.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"Synaptotagmin-11 (Syt11) is a calcium-insensitive, transmembrane vesicular trafficking protein that resides on post-Golgi/endosomal and recycling vesicles distinct from synaptic vesicles, where it negatively regulates membrane internalization and modulates secretion across neurons, microglia, and astrocytes [#2, #3]. In neurons Syt11 restrains synaptic vesicle endocytosis and spontaneous transmission through direct, Ca2+-independent interactions: its C2B domain binds and suppresses endophilin A1 to inhibit endocytosis and vesicle pool replenishment [#6], while its C2A domain binds the non-canonical SNARE vti1a to suppress spontaneous excitatory release [#4]. Syt11 also scaffolds presynaptic signaling by recruiting the GABAB receptor subunit KCTD16 and Cav2.2 channels to post-Golgi vesicles and stabilizing them at the plasma membrane by limiting constitutive internalization, supporting GABAB-mediated presynaptic inhibition and long-term potentiation and memory [#7, #2]. In microglia Syt11 inhibits activation, cytokine secretion, and phagocytosis of α-synuclein fibrils through binding vti1a/vti1b via its linker domain [#3, #8], and in astrocytes it stabilizes caveolae and restrains caveolae-mediated endocytosis through interactions with cavin1 and EHD2, conferring mechanoprotection [#11]. Syt11 is a short-lived protein degraded by the ubiquitin-proteasome system, and is the physiological substrate of the E3 ligase parkin; loss of parkin causes Syt11 accumulation that is mechanistically sufficient to impair dopamine release and drive late-onset dopaminergic neurodegeneration, identifying Syt11 as a key mediator of Parkinson's disease-like neurotoxicity [#1, #20, #14]. Palmitoylation at Cys39/Cys40 stabilizes Syt11 against endolysosomal degradation and promotes α-synuclein binding to membranes, shifting α-synuclein toward its aggregation-prone monomeric form [#5]. Beyond the nervous system, Syt11 acts as a trafficking and scaffolding factor in cancer, binding the MKK7–JNK1 module to promote EMT-related gene expression in gastric cancer [#9] and cooperating with Impad1 to control Golgi morphology and the invasive secretome [#10].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Established that Syt11 transcription is epigenetically and cis-regulated, the first mechanistic handle on how its levels are set before any functional role was known.\",\n      \"evidence\": \"EMSA and reporter assays with methylated and polymorphic promoter constructs\",\n      \"pmids\": [\"15777718\", \"17192956\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Does not connect promoter regulation to a specific cellular function\", \"Disease association is correlative\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Resolved where Syt11 acts in neurons, showing it is targeted to presynaptic vesicles and plasma membrane and recruited by neuroligins, placing it at synaptic membranes rather than postsynaptic sites.\",\n      \"evidence\": \"Immunogold EM, neuroligin co-culture, and fractionation in rat hippocampal neurons\",\n      \"pmids\": [\"22960622\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence of synaptic localization not established\", \"Molecular partners mediating vesicle targeting unknown\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Provided the first domain-level interaction map, distinguishing C2A (vti1a) from C2B (SND1, Ago2, FMRP) binding and linking Syt11 to RISC components in β-cells.\",\n      \"evidence\": \"Co-IP, pull-down, and domain-deletion constructs in pancreatic β-cells\",\n      \"pmids\": [\"24882364\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional role of RISC association not demonstrated\", \"Single-cell-type, single-study evidence\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Connected Syt11 to lysosomal/autophagic homeostasis by showing ATP13A2 loss lowers Syt11 transcriptionally (via mTORC1/TFEB) and post-translationally, with reduced Syt11 itself causing lysosomal dysfunction.\",\n      \"evidence\": \"Knockdown, epistasis, transcriptional reporters, ubiquitination and lysosomal assays\",\n      \"pmids\": [\"27278822\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct molecular mechanism by which Syt11 supports lysosomal function not defined\", \"Link to dopaminergic neuron survival not tested here\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Defined an immune-regulatory function, showing Syt11 suppresses microglial cytokine secretion and phagocytosis and restrains NF-κB, broadening its role beyond neurons.\",\n      \"evidence\": \"shRNA knockdown with rescue, ELISA, NF-κB reporter, phagocytosis and localization assays in primary microglia\",\n      \"pmids\": [\"28686317\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct binding partner mediating cytokine suppression not yet identified at this stage\", \"In vivo relevance not tested\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified Syt11 as a physiological parkin substrate and showed its accumulation impairs dopamine release and drives dopaminergic degeneration, providing a mechanistic basis for parkin-linked Parkinson's disease.\",\n      \"evidence\": \"Viral overexpression, knockout mice, dopamine measurements, EM, and genetic rescue in vivo\",\n      \"pmids\": [\"29311685\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Endocytic effector mediating the dopamine-release defect not yet identified here\", \"Whether endogenous accumulation alone is sufficient not resolved at this stage\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Characterized Syt11's vesicle identity and core neuronal phenotype, placing it on activity-recycling trafficking endosomes whose loss impairs LTP and memory while sparing fast transmitter release.\",\n      \"evidence\": \"Constitutive and conditional knockout mice, live imaging, electrophysiology, behavior, fractionation\",\n      \"pmids\": [\"30808661\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of slow desynchronized exocytosis unresolved\", \"Effectors linking the vesicle pool to LTP not defined here\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Extended Syt11's endocytic-control function to astrocytes, identifying cavin1 and EHD2 as direct partners through which it stabilizes caveolae and provides mechanoprotection.\",\n      \"evidence\": \"Knockout astrocytes, EM, live imaging, Co-IP, endocytosis and hypoosmotic stimulation assays\",\n      \"pmids\": [\"31908017\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Structural basis of cavin1/EHD2 binding not mapped\", \"Single-lab evidence\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Quantified Syt11 turnover, establishing it as a short-lived proteasome substrate whose degradation is activity- and parkin-dependent in neurons but parkin-independent in astrocytes.\",\n      \"evidence\": \"Cycloheximide chase, MG132, activity stimulation, parkin manipulation across neurons and astrocytes\",\n      \"pmids\": [\"32976921\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"The non-parkin E3 ligase in astrocytes not identified here\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Pinpointed the molecular target for Syt11's suppression of spontaneous release, mapping a high-affinity C2A–vti1a interaction whose disruption reverses the knockout phenotype.\",\n      \"evidence\": \"KO and overexpression in hippocampal neurons, mEPSC recording, GST pull-down, Co-IP, domain mapping, vti1a knockdown rescue\",\n      \"pmids\": [\"34599505\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How vti1a binding mechanically suppresses fusion not resolved\", \"Relationship to the endosomal vesicle pool not integrated\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealed non-neural functions of Syt11 as a signaling scaffold (MKK7–JNK1) driving EMT in gastric cancer and as an Impad1 partner controlling Golgi morphology and the invasive secretome.\",\n      \"evidence\": \"Phospho-kinase array, Co-IP, shRNA, xenograft and metastasis assays; interaction and secretome studies in lung cancer\",\n      \"pmids\": [\"35768842\", \"36170810\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether scaffolding and trafficking roles are mechanistically linked unclear\", \"Single-lab evidence for each context\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Showed Syt11 localizes to insulin granules and suppresses insulin secretion upstream of exocytosis, extending its secretion-braking role to pancreatic β-cells.\",\n      \"evidence\": \"siRNA knockdown, insulin ELISA, patch-clamp, confocal co-localization in INS-1 cells\",\n      \"pmids\": [\"35753051\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular effector in β-cells not identified\", \"Single-lab, single-study\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Identified endophilin A1 as the C2B effector through which Syt11 inhibits synaptic vesicle endocytosis, directly linking its trafficking role to the dopamine-release defect seen with accumulation.\",\n      \"evidence\": \"KO mice, calyx of Held electrophysiology, Co-IP, peptide competition in vitro and in vivo, EndoA1 knockdown rescue\",\n      \"pmids\": [\"37474308\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural model of the C2B–EndoA1 interface not defined\", \"How endocytic braking integrates with vti1a-dependent fusion control unresolved\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Established a post-translational switch—palmitoylation at Cys39/Cys40—that stabilizes Syt11 and links it to pathological α-synuclein membrane binding and aggregation.\",\n      \"evidence\": \"Acyl-RAC, site-directed mutagenesis, fractionation, pulse-chase, α-synuclein biochemistry in mouse and human brain\",\n      \"pmids\": [\"36787382\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Palmitoyltransferase responsible not identified\", \"Causal contribution to in vivo neurodegeneration not directly tested here\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Confirmed in vivo the microglial immune-suppressive role and mapped its linker-domain binding to vti1a/vti1b, with a competitive peptide phenocopying knockdown.\",\n      \"evidence\": \"Inducible microglia-specific cKO, LPS and α-synuclein fibril models, Co-IP, competitive peptide inhibition\",\n      \"pmids\": [\"37924268\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How vti1a/vti1b binding restrains conventional cytokine secretion mechanistically unclear\", \"Interplay with neuronal Syt11 loss in PD not addressed\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Defined Syt11 as a scaffold assembling presynaptic GABAB receptor/Cav2.2 signaling complexes and stabilizing them at the membrane, providing a mechanism for its support of presynaptic inhibition.\",\n      \"evidence\": \"Reciprocal Co-IP, co-localization, KO neurons, electrophysiology, internalization assays\",\n      \"pmids\": [\"38698221\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Binding interfaces for KCTD16 and Cav2.2 not mapped\", \"Relationship between scaffolding and endocytic-braking functions unresolved\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Demonstrated a developmental-window-specific role, where adolescent dopamine-neuron Syt11 loss produces persistent dopamine over-transmission and schizophrenia-like behavior reversible by D2R-targeted drugs.\",\n      \"evidence\": \"Temporally controlled dopamine-neuron conditional KO, behavior, dopamine measurements, pharmacological rescue\",\n      \"pmids\": [\"39632880\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular basis of the adolescent-specific requirement unknown\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Established Syt11 accumulation as mechanistically sufficient for parkin-associated PD and explained why parkin KO is phenotypically mild via compensatory Syt11 upregulation.\",\n      \"evidence\": \"Parkin KO and adult viral KD comparison, Syt11 overexpression sufficiency tests, dopamine and behavioral readouts\",\n      \"pmids\": [\"39901263\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of developmental Syt11 compensation not defined\", \"Single-lab study\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified VHL as a second E3 ligase that directly binds and proteasomally degrades Syt11, downregulating SPINK1 and suppressing gastric cancer growth, broadening Syt11's degradation control beyond parkin.\",\n      \"evidence\": \"Co-IP, cycloheximide chase, MG132, ubiquitination assay, transcriptomics, invasion/growth assays\",\n      \"pmids\": [\"40576306\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether VHL regulates Syt11 in neurons not tested\", \"Single-lab study\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unknown how Syt11's distinct domain-specific effector interactions (C2A–vti1a, C2B–EndoA1, linker–vti1a/vti1b, scaffolding of KCTD16/Cav2.2) are coordinated on a single vesicle population and how this integration is tuned across neurons, glia, and peripheral cells.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No structural model integrating the multiple binding surfaces\", \"No single study reconciles fusion-suppression and endocytosis-braking roles\", \"Cell-type-specific effector usage not systematically compared\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0060090\", \"supporting_discovery_ids\": [4, 6, 7, 11]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 6, 7]},\n      {\"term_id\": \"GO:0008289\", \"supporting_discovery_ids\": [5]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0031410\", \"supporting_discovery_ids\": [2, 3, 7]},\n      {\"term_id\": \"GO:0005794\", \"supporting_discovery_ids\": [3, 10]},\n      {\"term_id\": \"GO:0005768\", \"supporting_discovery_ids\": [2, 3]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [7, 11, 17]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-5653656\", \"supporting_discovery_ids\": [1, 2, 6, 11]},\n      {\"term_id\": \"R-HSA-112316\", \"supporting_discovery_ids\": [2, 4, 7]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [3, 8]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [1, 9, 20]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"VTI1A\", \"SH3GL2\", \"KCTD16\", \"CACNA2/Cav2.2\", \"VTI1B\", \"CAVIN1\", \"EHD2\", \"PARK2/parkin\"],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":7,"faith_total":7,"faith_pct":100.0}}